根治性切除术后联合肝细胞癌和胆管细胞癌的长期预后与肝细胞癌和胆管细胞癌的比较。

Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.

机构信息

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, Republic of Korea.

出版信息

J Clin Gastroenterol. 2011 Jan;45(1):69-75. doi: 10.1097/MCG.0b013e3181ce5dfa.

DOI:10.1097/MCG.0b013e3181ce5dfa

PMID:20142755

Abstract

GOAL

In this study, we attempted to evaluate the prognosis of combined hepatocellular and cholangiocarcinoma (cHCC-CC) with comparison to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CC).

BACKGROUND

The prognosis of cHCC-CC has not been fully elucidated. In this study, we attempted to evaluate the prognosis of cHCC-CC with comparison to HCC and CC.

STUDY

Consecutive patients who underwent curative resection for cHCC-CC at a single tertiary care center in Korea and their age, sex, and Child-Turcotte-Pugh class matched HCC and CC patients were included. We evaluated time-to-recurrence (TTR) and overall survival (OS) of cHCC-CC cases and compared them with HCC and CC patients.

RESULTS

Thirty cHCC-CC, 60 HCC, and 60 CC patients were included. For cHCC-CC group, the median TTR and OS were 5.4 and 18.0 months. After adjustment for confounding factors, the cHCC-CC group had a shorter TTR than did HCC group [relative risk (RR), 2.76; P<0.001] and CC group (RR, 2.00; P=0.013), and a shorter OS than HCC group (RR, 4.70; P<0.001). Compared with the each stage I diseases, cHCC-CC had shorter TTR than HCC (RR, 4.59; P=0.001) and CC (RR, 2.74, P=0.015) and shorter OS than HCC (RR, 9.35; P=0.001).

CONCLUSIONS

The results of this study indicated that cHCC-CC had a significantly poorer prognosis than HCC and CC even after curative resection.

摘要

目的

本研究旨在评估合并肝细胞癌和胆管细胞癌（cHCC-CC）与肝细胞癌（HCC）和肝内胆管细胞癌（CC）相比的预后。

背景

cHCC-CC 的预后尚未完全阐明。在本研究中，我们试图通过与 HCC 和 CC 进行比较来评估 cHCC-CC 的预后。

研究

连续纳入在韩国一家三级保健中心接受根治性切除治疗的 cHCC-CC 患者及其年龄、性别和 Child-Turcotte-Pugh 分级匹配的 HCC 和 CC 患者。我们评估了 cHCC-CC 病例的无复发生存时间（TTR）和总生存期（OS），并将其与 HCC 和 CC 患者进行了比较。

结果

纳入 30 例 cHCC-CC、60 例 HCC 和 60 例 CC 患者。cHCC-CC 组的中位 TTR 和 OS 分别为 5.4 个月和 18.0 个月。在调整混杂因素后，cHCC-CC 组的 TTR 短于 HCC 组[相对风险（RR），2.76；P<0.001]和 CC 组（RR，2.00；P=0.013），OS 短于 HCC 组（RR，4.70；P<0.001）。与每个 I 期疾病相比，cHCC-CC 的 TTR 短于 HCC（RR，4.59；P=0.001）和 CC（RR，2.74，P=0.015），OS 短于 HCC（RR，9.35；P=0.001）。